PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing of utreloxastat could achieve a two-point difference on ALSFRS, an instrument for evaluating the functional status of ALS patients. The drug candidate fell short of that bar.
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down
The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis drug failed to halt disease progression.
PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect PTC, instead postulating that the upcoming FDA decision on its phenylketonuria candidate sepiapterin will be a stronger driver of the biotech’s stock.
PTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpoint
PTC Therapeutics (PTCT) announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing
PTC's utreloxastat fails Phase 2 clinical study for ALS
PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints. The biotech company said the drug failed to demonstrate statistical significance in the slowing of disease progression,
ALS News Today3h
Brain scans may predict ALS risk in C9ORF72 mutation carriers
Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...
An artist with ALS creates beautiful portraits of people with the fatal disease
ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...
He runs Upstate NY’s first Chick-fil-A without moving or speaking a word: ‘I’m still climbing’
Since Jimmer Szatkowski opened Upstate New York’s first Chick-fil-A in 2018, he’s been at the restaurant most every day. He’s ...
CSR Wire1h
AI-Powered Communication Solution for People Living With ALS Revealed at Lenovo Tech World
At Lenovo Tech World ’24, global technology leader Lenovo and the Scott-Morgan Foundation (SMF), a non-profit pioneering ...
Inspiring Ogden High football coach Erik Thompson calling it a career — and what a career it was
Thompson, who has spent the latter part of his coaching career while suffering from ALS, is much more than a fine football ...
Live Science on MSN3d
'Exercise juice' released by muscles helps nerves grow, study finds
In a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...
Wedbush upgrades Voyager to Outperform on pipeline progress
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the ...
Neuralink wants its brain chip to control a robot arm next
There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...
IIT-BHU developing med device with potential to cure sclerosis
A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...